Vittorio Sebastiano

Vittorio Sebastiano earned his PhD at the Università di Pavia in Italy and completed postdoctoral training at the Max Planck Institute in Germany before joining Stanford, where he has been an associate professor in the Department of Obstetrics and Gynecology, affiliated with the Stanford Institute for Stem Cell Biology and Regenerative Medicine, since 2014 [1].

In 2018 Sebastiano co-founded Turn Biotechnologies to commercialize a reprogramming approach his lab developed, which the company calls Epigenetic Reprogramming of Aging, or ERA [1]. Unlike full cellular reprogramming, which uses the four Yamanaka factors to revert a cell all the way back to a pluripotent stem-cell state and erase its identity, Turn Bio's ERA platform uses mRNA to deliver a transient, partial reprogramming signal intended to reverse some epigenetic aging markers while preserving the cell's original identity and function, an approach also being pursued in different forms by other reprogramming researchers referenced across this wiki [1]. Sebastiano chaired Turn Bio's Scientific Advisory Board from 2018 to August 2022, when he transitioned into the more operationally embedded role of Head of Research for the company, a move a PR Newswire announcement described as putting him in charge of overseeing all of Turn Bio's research [1].

A press release covering that transition stated that Sebastiano's Stanford team was responsible for confirming that human cells could be successfully reprogrammed using the ERA platform, tying the company's core technical claim directly to research conducted in his own academic lab [1]. This is a direct example of a researcher validating, in an academic setting, the same technology his own company is built on and will eventually sell, a structural overlap worth naming explicitly even where the individual experiments themselves are conducted to normal peer-review standards.

Turn Bio's application of the ERA platform has extended into cosmetic and dermatological uses. A 2024 paper in Dermatologic Surgery on transient epigenetic reprogramming for skin rejuvenation, co-authored by Turn Bio-affiliated researchers including Sebastiano, describes applying the reprogramming technology to skin rejuvenation, a commercial application distinct from, and more immediately monetizable than, the company's longer-term aging-reversal therapeutic ambitions [2]. Positioning a still-early-stage reprogramming technology as a near-term cosmetic product is a meaningfully different claim than positioning it as a validated systemic anti-aging therapy, and readers should track which claim, cosmetic or systemic, is being made in any given piece of Turn Bio-affiliated content.

Sebastiano's academic publication record on transient reprogramming does include peer-reviewed work demonstrating epigenetic age reduction and some functional improvements in reprogrammed cells in laboratory settings, but as with most reprogramming research covered in this wiki, this remains preclinical, cell-culture and animal-model evidence; no completed human clinical trial data validating ERA's systemic anti-aging effects in people has been identified in available sources.

The plain takeaway: Sebastiano's transient reprogramming research is a serious, differentiated approach within the broader reprogramming field, distinct from full Yamanaka-factor reprogramming, and Turn Bio's move into cosmetic skin applications is a plausible nearer-term commercial path for the technology, but Sebastiano's dual role as both the company's technical validator and an academic principal investigator means the company's central technical claims currently rest heavily on research from his own lab rather than fully independent replication.